Pulmonary Embolism
What is a Pulmonary Embolism?
Pulmonary embolism (PE), also called pulmonary thromboembolism (PTE), is the sudden obstruction of one or more pulmonary arteries by a blood clot (thrombus). This clot most often originates from deep vein thrombosis (DVT) of the lower limbs (phlebitis), which breaks loose and travels through the venous circulation to the lungs. Pulmonary embolism is a medical emergency that can lead to acute respiratory failure, right heart failure, and death without rapid treatment. In Tunisia, our pulmonology, cardiology, and intensive care departments are equipped to manage this pathology 24/7.
Why is it Urgent to Diagnose and Treat a Pulmonary Embolism?
Pulmonary embolism is the third leading cause of cardiovascular death after myocardial infarction and stroke. Its severity depends on the extent of vascular obstruction:
- Non-massive pulmonary embolism: moderate dyspnea, little hemodynamic impact.
- Submassive pulmonary embolism: signs of right ventricular dysfunction on echocardiography, elevated biological markers.
- Massive pulmonary embolism: obstruction > 50% of the pulmonary arterial bed, hypotension (SBP < 90 mmHg), shock, cardiac arrest. Mortality without treatment exceeds 30%.
Rapid management (anticoagulation, thrombolysis, or even surgical or endovascular embolectomy) significantly improves prognosis.
What are the Risk Factors and Warning Signs?
Risk factors for venous thromboembolic disease are numerous:
- Prolonged immobilization (bed rest, long-distance travel > 4h, cast).
- Recent surgery (orthopedic, abdominal, neurosurgical).
- Cancers (pancreas, lung, colon, breast, ovary).
- Pregnancy and postpartum.
- Estrogen use (oral contraceptives, menopausal hormone therapy).
- Thrombophilia (antithrombin deficiency, protein C deficiency, protein S deficiency, factor V Leiden, prothrombin gene mutation).
- Advanced age, obesity, smoking, hypertension, heart failure.
Warning signs of pulmonary embolism are:
- Sudden unexplained dyspnea (shortness of breath), often severe.
- Chest pain (typically retrosternal, sometimes pleuritic or pseudo-anginal).
- Tachycardia (rapid pulse > 100/min).
- Hemoptysis (bloody sputum).
- Signs of deep vein thrombosis: swollen, red, painful, warm leg.
- In severe forms: hypotension, presyncope, syncope, or even cardiac arrest.
With any suspicion, emergency management at the emergency department is required.
How is the Diagnosis Made in Tunisia?
The diagnosis of pulmonary embolism is based on a rapid clinical and paraclinical approach:
- Clinical assessment: clinical probability score (Wells score, Geneva rule).
- D-Dimer assay: biological marker of fibrin degradation. A normal level (< 500 ng/mL) in a patient with low clinical probability virtually rules out pulmonary embolism.
- Pulmonary CT angiography (Angio-CT): reference examination, available in Tunisia 24/7. It directly visualizes the clot(s) in the pulmonary arteries.
- Transthoracic echocardiography: searches for right ventricular dysfunction (sign of severity).
- Arterial blood gas: hypoxemia (low PaO2) and hypocapnia (low PaCO2) are often present, but not specific.
- Electrocardiogram (ECG): looks for signs of acute cor pulmonale (S1Q3T3, incomplete right bundle branch block, T wave inversion in V1-V4).
In Tunisia, the median time to obtain a CT angiography is less than 2 hours in equipped hospital centers.
What Treatments are Available?
The management of pulmonary embolism is based on severity stratification and the use of appropriate treatments.
Anticoagulation (Basic Treatment, Initiated Upon Suspicion)
Anticoagulant therapy should be started without waiting for imaging results if the clinical probability is high. It aims to prevent extension of the existing clot and the formation of new thrombi.
- Unfractionated heparin (UFH): intravenous route, used in intensive care (allows rapid titration and reversibility with protamine).
- Low molecular weight heparins (LMWH): enoxaparin (Lovenox®), tinzaparin (Innohep®), dalteparin (Fragmin®). Used in stable patients, subcutaneously.
- Direct oral anticoagulants (DOACs): rivaroxaban (Xarelto®), apixaban (Eliquis®) can be used immediately after stabilization, without heparin bridging.
The duration of anticoagulant treatment is at least 3 to 6 months, and may be extended lifelong in cases of persistent risk factors, thrombophilia, or recurrence.
Thrombolysis (Treatment of Massive PE)
Thrombolysis (intravenous administration of a fibrinolytic agent: tenecteplase, alteplase) rapidly dissolves the clot. It is indicated in cases of massive pulmonary embolism (hypotension, shock) or submassive with signs of severity (severe RV dysfunction). Thrombolysis reduces mortality but increases the risk of bleeding (intracranial hemorrhage in 1-2% of cases). It should be performed within 48 hours of symptom onset.
Interventional Treatment (Mechanical Embolectomy)
For patients with a contraindication to thrombolysis or persistent hemodynamic instability after thrombolysis, pulmonary embolectomy may be offered:
- Endovascular embolectomy (catheter thrombectomy): clot fragmentation or aspiration, a minimally invasive technique performed in interventional radiology.
- Surgical embolectomy: via thoracotomy with cardiopulmonary bypass (reserved for expert centers).
Vena Cava Filter
Placement of an inferior vena cava filter (under local anesthesia, via the femoral vein) is indicated in patients with recurrent pulmonary embolism despite well-conducted anticoagulant therapy, or with an absolute contraindication to anticoagulants (recent cerebral hemorrhage, extensive gastric ulcer). The filter captures clots from the lower limbs before they reach the pulmonary artery.
Supportive Care in Intensive Care
Severe forms require hospitalization in intensive care: oxygen therapy, NIV or mechanical ventilation, vasopressor support (norepinephrine), invasive hemodynamic monitoring.
What are the Risks and Complications?
Complications of pulmonary embolism are:
- Thromboembolic recurrence (even under anticoagulants, 2-5% of cases).
- Chronic thromboembolic pulmonary hypertension (CTEPH): long-term sequela, characterized by persistent dyspnea and pulmonary arterial hypertension, requiring specific treatment (lifelong anticoagulants, or even endarterectomy).
- Post-embolic syndrome: chronic chest pain, functional limitation.
- Major bleeding (under anticoagulants or thrombolysis): intracranial hematoma (1-2% after thrombolysis), gastrointestinal bleeding, retroperitoneal bleeding.
- Chronic right heart failure (in massive forms).
What to Do After a Pulmonary Embolism? Follow-up and Secondary Prevention
Hospital discharge (average duration 5 to 10 days depending on severity) marks the beginning of a prolonged follow-up phase:
- Follow-up consultation at 1, 3, 6, and 12 months (pulmonologist, cardiologist).
- Continuation of anticoagulant treatment for the prescribed duration (3 to 12 months, or lifelong).
- Thrombophilia workup (if young patient, family history, recurrence).
- Control echocardiography at 3-6 months to screen for residual pulmonary hypertension.
- Wearing elastic compression stockings in case of deep vein thrombosis sequelae.
- Lifestyle measures: weight loss, smoking cessation, regular physical activity, hydration, avoiding prolonged immobilization.
- Control lung scan or CT angiography at 6-12 months if suspicion of chronic PH.
In Tunisia, we offer a personalized follow-up program with control consultations at very competitive rates.
Why Choose Tunisia for Your Management?
Tunisia has high-level pulmonologists, cardiologists, and intensivists, trained in the best European centers (Paris, Lyon, Marseille, Brussels, Geneva). Diagnostic equipment is modern: 64 and 128-slice CT scanners for high-quality pulmonary CT angiography, state-of-the-art echocardiographs, 24/7 hemostasis laboratories. Anticoagulant (LMWH, DOACs) and thrombolytic treatments are available and administered according to international guidelines (ESC 2019, CHEST 2021). Management delays are very short (emergency admission, CT angiography in less than 2 hours) and costs are up to 60-80% lower than European rates. Our all-inclusive packages include hospitalization, imaging tests, anticoagulant therapy (heparin, DOACs), and 3-month follow-up.